Clinical Trial Update: 3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal Keratoconjunctivitis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating 3% diquafosol ophthalmic solution for active moderate-to-severe Vernal keratoconjunctivitis; currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vernal Keratoconjunctivitis

Drugs mentioned

• Diquafosol ophthalmic solution (diquafosol)

Snippet

Sponsor: The University of Hong Kong | Conditions: Vernal Keratoconjunctivitis | Phase 3 | Status: NOT_YET_RECRUITING